NASDAQ:CATB - Catabasis Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$7.19 -0.11 (-1.51 %)
(As of 03/25/2019 11:31 AM ET)
Previous Close$7.30
Today's Range$7.08 - $7.40
52-Week Range$3.60 - $20.40
Volume5,015 shs
Average Volume271,632 shs
Market Capitalization$82.61 million
P/E Ratio-1.40
Dividend YieldN/A
Beta1.64

Headlines

Catabasis Pharmaceuticals (NASDAQ CATB) News Headlines

Source:
DateHeadline
Q1 2019 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Lifted by WedbushQ1 2019 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Lifted by Wedbush
www.americanbankingnews.com - March 21 at 8:53 AM
Catabasis Pharmaceuticals (CATB) Buy Rating Reiterated at WedbushCatabasis Pharmaceuticals' (CATB) Buy Rating Reiterated at Wedbush
www.americanbankingnews.com - March 18 at 4:24 PM
Catabasis Pharmaceuticals (CATB) Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPSCatabasis Pharmaceuticals (CATB) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - March 15 at 11:33 AM
Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMTEdited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT
finance.yahoo.com - March 15 at 8:30 AM
Catabasis Pharma +2% on FY 2018 resultsCatabasis Pharma +2% on FY 2018 results
seekingalpha.com - March 14 at 7:20 PM
Catabasis Pharmaceuticals (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call TranscriptCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 7:20 PM
Catabasis (CATB) Beats Earnings in Q4, Revenues NilCatabasis (CATB) Beats Earnings in Q4, Revenues Nil
finance.yahoo.com - March 14 at 7:20 PM
Catabasis Pharmaceuticals, Inc. (CATB)Catabasis Pharmaceuticals, Inc. (CATB)
finance.yahoo.com - March 14 at 8:28 AM
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business ProgressCatabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress
finance.yahoo.com - March 14 at 8:28 AM
Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare ConferenceCatabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference
finance.yahoo.com - March 13 at 8:13 AM
Townsquare (TSQ) to Report Q4 Earnings: Whats in the Cards? - NasdaqTownsquare (TSQ) to Report Q4 Earnings: What's in the Cards? - Nasdaq
www.nasdaq.com - March 8 at 7:50 PM
Is a Beat in Store for Catabasis (CATB) This Earnings Season?Is a Beat in Store for Catabasis (CATB) This Earnings Season?
www.zacks.com - March 7 at 8:33 AM
Catabasis Pharmaceuticals (CATB) Scheduled to Post Quarterly Earnings on ThursdayCatabasis Pharmaceuticals (CATB) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 7 at 1:47 AM
Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%
finance.yahoo.com - March 6 at 7:34 PM
 Analysts Anticipate Catabasis Pharmaceuticals Inc (CATB) Will Post Earnings of -$0.95 Per Share Analysts Anticipate Catabasis Pharmaceuticals Inc (CATB) Will Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - March 5 at 10:37 AM
Tonix Pharmaceuticals (TNXP) vs. Catabasis Pharmaceuticals (CATB) Financial SurveyTonix Pharmaceuticals (TNXP) vs. Catabasis Pharmaceuticals (CATB) Financial Survey
www.americanbankingnews.com - March 1 at 7:25 PM
Financial Survey: Strongbridge Biopharma (SBBP) versus Catabasis Pharmaceuticals (CATB)Financial Survey: Strongbridge Biopharma (SBBP) versus Catabasis Pharmaceuticals (CATB)
www.americanbankingnews.com - February 28 at 7:23 PM
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14
finance.yahoo.com - February 28 at 8:25 AM
Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular DystrophyCatabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
finance.yahoo.com - February 19 at 8:16 AM
Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of DirectorsCatabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
finance.yahoo.com - February 14 at 8:19 AM
Catabasis Pharmaceuticals down 20% on stock offeringCatabasis Pharmaceuticals down 20% on stock offering
seekingalpha.com - February 6 at 6:35 PM
Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public OfferingCatabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
finance.yahoo.com - February 6 at 6:35 PM
Catabasis readies equity offering; shares down 5% after hoursCatabasis readies equity offering; shares down 5% after hours
seekingalpha.com - February 5 at 6:30 PM
Catabasis Pharmaceuticals Announces Proposed Underwritten Public OfferingCatabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
finance.yahoo.com - February 5 at 6:30 PM
Catabasis Pharmaceuticals: My Long Thesis And AnalysisCatabasis Pharmaceuticals: My Long Thesis And Analysis
seekingalpha.com - January 16 at 8:20 AM
Is Catabasis Pharmaceuticals, Inc.’s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers?Is Catabasis Pharmaceuticals, Inc.’s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers?
finance.yahoo.com - January 15 at 6:08 PM
Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - January 14 at 10:40 AM
Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - January 11 at 6:40 PM
Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of DirectorsCatabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors
finance.yahoo.com - January 4 at 5:45 PM
Catabasis Gears Up for Late-Stage Duchenne Muscular Dystrophy TrialCatabasis Gears Up for Late-Stage Duchenne Muscular Dystrophy Trial
247wallst.com - January 4 at 7:30 AM
Catabasis Pharma up 6% on clinical advancement of DMD candidate edasalonexentCatabasis Pharma up 6% on clinical advancement of DMD candidate edasalonexent
seekingalpha.com - January 4 at 7:30 AM
Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for EnrollmentCatabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment
finance.yahoo.com - January 3 at 8:24 AM
Catabasis Pharmaceuticals Inc.Catabasis Pharmaceuticals Inc.
www.barrons.com - December 31 at 5:19 PM
Catabasis Pharmaceuticals Announces Reverse Stock Split - Business WireCatabasis Pharmaceuticals Announces Reverse Stock Split - Business Wire
www.businesswire.com - December 25 at 5:15 PM
Catabasis Pharmaceuticals Announces Reverse Stock SplitCatabasis Pharmaceuticals Announces Reverse Stock Split
finance.yahoo.com - December 24 at 8:16 AM
Catella Divests Card Issuing Operations in Luxembourg to Advanzia Bank and Completes Strategic ReviewCatella Divests Card Issuing Operations in Luxembourg to Advanzia Bank and Completes Strategic Review
finance.yahoo.com - December 18 at 8:21 AM
Catella and Söderberg & Partners in Strategic PartnershipCatella and Söderberg & Partners in Strategic Partnership
finance.yahoo.com - December 12 at 8:19 AM
Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy - Business WireCatabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy - Business Wire
www.businesswire.com - November 29 at 5:46 PM
Catabasis Wins With Early-Stage Duchenne Muscular Dystrophy StudyCatabasis Wins With Early-Stage Duchenne Muscular Dystrophy Study
247wallst.com - November 27 at 5:19 PM
Catabasis Pharma (CATB) Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in DMDCatabasis Pharma (CATB) Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in DMD
www.streetinsider.com - November 27 at 8:35 AM
Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular DystrophyCatabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
finance.yahoo.com - November 27 at 8:35 AM
Does The Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Price Fall With The Market?Does The Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Price Fall With The Market?
finance.yahoo.com - November 15 at 5:26 PM
Edited Transcript of CATB earnings conference call or presentation 13-Nov-18 1:30pm GMTEdited Transcript of CATB earnings conference call or presentation 13-Nov-18 1:30pm GMT
finance.yahoo.com - November 14 at 8:15 AM
Catabasis Pharma inks collaboration to explore potential of edasalonexent in Duchenne and Becker muscular dystrophiesCatabasis Pharma inks collaboration to explore potential of edasalonexent in Duchenne and Becker muscular dystrophies
seekingalpha.com - November 13 at 5:12 PM
Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q3 2018 Results - Earnings Call TranscriptCatabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 13 at 5:12 PM
Catabasis Pharmaceuticals: 3Q Earnings SnapshotCatabasis Pharmaceuticals: 3Q Earnings Snapshot
finance.yahoo.com - November 13 at 5:12 PM
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular DystrophiesCatabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies
finance.yahoo.com - November 13 at 8:16 AM
Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business ProgressCatabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress
finance.yahoo.com - November 13 at 8:16 AM
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular DystrophyCatabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
finance.yahoo.com - November 2 at 8:14 AM
Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on ...Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on ...
www.businesswire.com - November 1 at 8:12 AM
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel